To The Moon
Home
News
TigerAI
Log In
Sign Up
iams3by
+Follow
Posts · 4
Posts · 4
Following · 0
Following · 0
Followers · 0
Followers · 0
iams3by
iams3by
·
2022-02-04
Buy the dip
Sorry, this post has been deleted
看
2.11K
回复
Comment
点赞
1
编组 21备份 2
Share
Report
iams3by
iams3by
·
2022-01-14
It will climb back soon. Just have to be patience 😎
Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%
Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.Moderna, BioNtech and Pfize
Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%
看
1.79K
回复
Comment
点赞
4
编组 21备份 2
Share
Report
iams3by
iams3by
·
2022-01-13
Time to buy more
Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine
Pfizer announces positive top-line results from a Phase 3 study describing the safety and immunogen
Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine
看
2.51K
回复
Comment
点赞
Like
编组 21备份 2
Share
Report
iams3by
iams3by
·
2022-01-13
$Pfizer(PFE)$
Slowly but surely 😎
看
2.43K
回复
Comment
点赞
2
编组 21备份 2
Share
Report
Load more
No following yet
Most Discussed
{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"4104687611168670","uuid":"4104687611168670","gmtCreate":1641584542654,"gmtModify":1641584542654,"name":"iams3by","pinyin":"iams3by","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":0,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.30","exceedPercentage":"60.55%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":9091775572,"gmtCreate":1643953549673,"gmtModify":1676533875952,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104687611168670","authorIdStr":"4104687611168670"},"themes":[],"htmlText":"Buy the dip","listText":"Buy the dip","text":"Buy the dip","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9091775572","repostId":"1180306841","repostType":4,"isVote":1,"tweetType":1,"viewCount":2108,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9005970252,"gmtCreate":1642160840864,"gmtModify":1676533687588,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104687611168670","authorIdStr":"4104687611168670"},"themes":[],"htmlText":"It will climb back soon. Just have to be patience 😎","listText":"It will climb back soon. Just have to be patience 😎","text":"It will climb back soon. Just have to be patience 😎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005970252","repostId":"1141205139","repostType":2,"repost":{"id":"1141205139","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1642158579,"share":"https://ttm.financial/m/news/1141205139?lang=&edition=fundamental","pubTime":"2022-01-14 19:09","market":"us","language":"en","title":"Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141205139","media":"Tiger Newspress","summary":"Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.Moderna, BioNtech and Pfize","content":"<html><head></head><body><p>Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.</p><p>Moderna, BioNtech and Pfizer fell between 1% and 4%.<img src=\"https://static.tigerbbs.com/41f83c9f798e54250bcb5d6639f341d9\" tg-width=\"717\" tg-height=\"605\" referrerpolicy=\"no-referrer\"/></p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks tumbled in premarket trading. Novavax shares fell over 8%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-01-14 19:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.</p><p>Moderna, BioNtech and Pfizer fell between 1% and 4%.<img src=\"https://static.tigerbbs.com/41f83c9f798e54250bcb5d6639f341d9\" tg-width=\"717\" tg-height=\"605\" referrerpolicy=\"no-referrer\"/></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","PFE":"辉瑞"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141205139","content_text":"Vaccine stocks tumbled in premarket trading. Novavax shares fell over 8%.Moderna, BioNtech and Pfizer fell between 1% and 4%.","news_type":1,"symbols_score_info":{"NVAX":0.9,"MRNA":0.9,"BNTX":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1789,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002210808,"gmtCreate":1642027149507,"gmtModify":1676533672032,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104687611168670","authorIdStr":"4104687611168670"},"themes":[],"htmlText":"Time to buy more","listText":"Time to buy more","text":"Time to buy more","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002210808","repostId":"1117693983","repostType":2,"repost":{"id":"1117693983","kind":"news","pubTimestamp":1641989077,"share":"https://ttm.financial/m/news/1117693983?lang=&edition=fundamental","pubTime":"2022-01-12 20:04","market":"us","language":"en","title":"Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=1117693983","media":"Seeking Alpha","summary":"Pfizer announces positive top-line results from a Phase 3 study describing the safety and immunogen","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/PFE\">Pfizer </a> announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.</p><p>Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).</p><p>Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.</p><p>Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.</p><p>On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer reports positive results from Phase 3 study of PREVNAR 20 with COVID-19 vaccine\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-12 20:04 GMT+8 <a href=https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years ...</p>\n\n<a href=\"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/news/3787390-pfizer-reports-positive-results-from-phase-3-study-of-prevnar-20-with-covid-19-vaccine","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117693983","content_text":"Pfizer announces positive top-line results from a Phase 3 study describing the safety and immunogenicity of PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) in 570 adults in U.S. aged 65 years or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.Responses elicited by PREVNAR 20 for all 20 serotypes were similar whether given with a dose of the COVID-19 Vaccine (n=190) or with placebo (n=191).Responses to a booster dose of COVID-19 jab were also similar when given with PREVNAR 20 or given with placebo (n=189). The safety profile of co-administering PREVNAR 20 with a booster dose of COVID-19 shot generally reflected that observed with the Pfizer-BioNTech COVID-19 Vaccine booster dose.Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date.On June 8, 2021, FDA approved Pfizer's PREVNAR 20 for the prevention of invasive disease and pneumonia in adults age 18 years or older.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2506,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9002674413,"gmtCreate":1642008516633,"gmtModify":1676533671232,"author":{"id":"4104687611168670","authorId":"4104687611168670","name":"iams3by","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104687611168670","authorIdStr":"4104687611168670"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>Slowly but surely 😎","listText":"<a href=\"https://ttm.financial/S/PFE\">$Pfizer(PFE)$</a>Slowly but surely 😎","text":"$Pfizer(PFE)$Slowly but surely 😎","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9002674413","isVote":1,"tweetType":1,"viewCount":2434,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}